|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
|
AU782051B2
(en)
*
|
1996-06-03 |
2005-06-30 |
Case Western Reserve University |
Enhanced delivery via serpin enzyme complex receptor
|
|
US6387700B1
(en)
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
|
US7097829B2
(en)
*
|
1996-11-21 |
2006-08-29 |
Cedars-Sinai Medical Center |
Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
|
|
US6894031B1
(en)
*
|
1996-11-21 |
2005-05-17 |
Cedars-Sinai Medical Center |
Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
|
|
US6913926B2
(en)
*
|
1996-11-21 |
2005-07-05 |
Cedars-Sinai Medical Center |
Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
|
|
AU3758199A
(en)
*
|
1998-04-23 |
1999-11-08 |
Regents Of The University Of Michigan, The |
Peptides for efficient gene transfer
|
|
US6903077B1
(en)
|
1999-01-04 |
2005-06-07 |
University Of Vermont And State Agricultural College |
Methods and products for delivering nucleic acids
|
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
|
DE50015216D1
(de)
*
|
1999-11-08 |
2008-07-31 |
Ipf Pharmaceuticals Gmbh |
Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung
|
|
US7355019B2
(en)
*
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
|
EP1170373A1
(en)
*
|
2000-07-03 |
2002-01-09 |
Retina France |
Peptide-mediated ocular cell transfection
|
|
WO2002075306A1
(en)
*
|
2001-03-16 |
2002-09-26 |
Large Scale Biology Corporation |
Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications
|
|
AU2002256398A2
(en)
*
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
|
US6909030B2
(en)
*
|
2001-10-15 |
2005-06-21 |
Cedars-Sinai Medical Center |
PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
|
|
WO2004003160A2
(en)
*
|
2002-06-27 |
2004-01-08 |
University Of Washington |
Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
|
|
US20040014698A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
US20040016013A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
|
|
US20040014704A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent induces tolerance
|
|
JP2004179274A
(ja)
*
|
2002-11-26 |
2004-06-24 |
Hitachi Ltd |
光半導体装置
|
|
AU2003303218A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Ipf Pharmaceuticals |
Peptides and their use for the treatment of hiv infections
|
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
|
US20050208032A1
(en)
*
|
2004-01-16 |
2005-09-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
EP2281888B1
(en)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
DE102005005528A1
(de)
*
|
2005-01-30 |
2006-08-03 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Injizierbares Mittel zur zielgerichteten Behandlung von retinalen Ganglienzellen
|
|
WO2007127219A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute, Inc. |
Targeted delivery to leukocytes using protein carriers
|
|
JP5718570B2
(ja)
|
2006-08-01 |
2015-05-13 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
ベータミオシン重鎖の発現を活性化するマイクロｒｎａの同定
|
|
CA2670594A1
(en)
|
2006-12-06 |
2008-06-12 |
Medimmune, Llc |
Interferon alpha-induced pharmacodynamic markers
|
|
AU2008247398B2
(en)
|
2007-05-03 |
2013-10-10 |
Medimmune, Llc |
Interferon alpha-induced pharmacodynamic markers
|
|
KR101554996B1
(ko)
|
2007-07-31 |
2015-09-23 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
섬유증을 조절하는 마이크로-ｒｎａ 집단 및 이의 용도
|
|
EP2535350B1
(en)
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
|
EP2265291B1
(en)
|
2008-03-17 |
2016-10-19 |
The Board of Regents of The University of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
|
HRP20170374T1
(hr)
*
|
2008-09-26 |
2017-05-05 |
Ucb Biopharma Sprl |
Biološki proizvodi
|
|
US8492133B2
(en)
|
2009-01-20 |
2013-07-23 |
Ramot At Tel Aviv University, Ltd. |
MIR-21 promoter driven targeted cancer therapy
|
|
CA2758531C
(en)
|
2009-04-14 |
2018-11-13 |
Derren Barken |
Inflammatory bowel disease prognostics
|
|
WO2011030107A1
(en)
*
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
|
DK3252068T3
(da)
|
2009-10-12 |
2025-08-25 |
Larry J Smith |
Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
|
|
WO2011060098A1
(en)
|
2009-11-10 |
2011-05-19 |
Prometheus Laboratories Inc. |
Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
|
|
EP2542678B1
(en)
|
2010-03-04 |
2017-04-12 |
InteRNA Technologies B.V. |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
|
|
NZ605420A
(en)
|
2010-07-06 |
2015-02-27 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
JP6010541B2
(ja)
*
|
2010-11-15 |
2016-10-19 |
エイボン プロダクツ インコーポレーテッド |
生体機能的に固定された持ちの良い化粧品
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
AU2012325798B2
(en)
|
2011-10-21 |
2015-11-26 |
Société des Produits Nestlé S.A. |
Methods for improving inflammatory bowel disease diagnosis
|
|
US10174314B2
(en)
|
2011-12-22 |
2019-01-08 |
Interna Technologies B.V. |
MiRNA for treating head and neck cancer
|
|
JP2015510889A
(ja)
|
2012-03-09 |
2015-04-13 |
ノースイースタン・ユニバーシティ |
中枢神経系障害を治療するための核酸ナノ粒子を中枢神経系へ送達する方法
|
|
EP3800256A1
(en)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
|
|
US20150337375A1
(en)
|
2012-12-21 |
2015-11-26 |
The Trustees Of Columbia University In The City Of New York |
Biomarkers for chronic traumatic encephalopathy
|
|
US9758835B2
(en)
|
2013-03-15 |
2017-09-12 |
Baylor Research Institute |
Ulcerative colitis (UC)-associated colorectal neoplasia markers
|
|
EP3019175B1
(en)
|
2013-07-11 |
2019-12-04 |
The Trustees of Columbia University in the City of New York |
Micrornas that silence tau expression
|
|
WO2015073707A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
EP2960252A1
(en)
*
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase for treatment of immunosuppression
|
|
EP3472193A4
(en)
|
2016-06-20 |
2020-01-08 |
The Board of Trustees of the Leland Stanford Junior University |
CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION
|
|
US11958911B2
(en)
*
|
2017-02-10 |
2024-04-16 |
Shanghai Benemae Pharmaceutical |
Anti-coagulation factor XI antibody
|
|
JP6784973B2
(ja)
*
|
2017-03-30 |
2020-11-18 |
国立研究開発法人産業技術総合研究所 |
単層カーボンナノチューブ
|
|
EP3609519B1
(en)
|
2017-04-11 |
2025-11-26 |
University of Maryland, Baltimore |
Compositions and methods for treating inflammation and cancer
|
|
EP3682004A4
(en)
|
2017-09-15 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
MULTIPLEX PRODUCTION AND BARCODING OF GENETICALLY MODIFIED CELLS
|
|
WO2019068766A1
(en)
|
2017-10-03 |
2019-04-11 |
Aptahem Ab |
NUCLEIC ACID MOLECULE HAVING ANTI-INFLAMMATORY, ANTI-COAGULANT AND ORGAN PROTECTIVE PROPERTIES
|
|
AU2018358016A1
(en)
|
2017-11-03 |
2020-05-07 |
Interna Technologies B.V. |
MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
|
CN109836500A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
US20250011787A1
(en)
|
2021-10-21 |
2025-01-09 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Retroelement-generated transcription factor decoys
|
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
CA3255280A1
(en)
|
2022-03-25 |
2023-09-28 |
The Regents Of The University Of California |
PRODUCTION OF REVERSE TRANSCRIPT DNA (RT-DNA) BY MEANS OF REVERSE RETRON TRANSCRIPTASE FROM EXOGENOUS DNA
|
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
|
CA3246348A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
RT-DNA AND RETRONS FIDELITY GENOMIC EDITING
|
|
EP4504918A1
(en)
|
2022-04-07 |
2025-02-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Continuous multiplexed phage genome engineering using a retron editing template
|
|
WO2024036232A2
(en)
*
|
2022-08-09 |
2024-02-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|